Business
BELLUS HEALTH REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2010 AND ANNOUNCES RECEIPT OF US$5 MILLION FROM PARTNER CELTIC THERAPEUTICS
BELLUS HEALTH REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2010 AND ANNOUNCES RECEIPT OF...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Nov. 10, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nLAVAL, QC, Nov. 10 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS\n Health" or the "Company") reported today its financial results for the\n third quarter ended September 30, 2010. All currency figures reported\n in this press release, including comparative figures, are in Canadian\n dollars, unless otherwise specified.\n\n\n"We are pleased with the progress made in the past months in\n implementing our strategic initiatives to limit our operating costs\n while continuing to add value to the products in our pipeline and are\n looking forward to important developments in the fourth quarter of\n 2010," said Roberto Bellini, President and Chief Executive Officer of\n BELLUS Health. "We have received the second installment of US$5 million\n in connection with the KIACTA™ Asset Purchase and License Agreement\n from our strategic partner Celtic Therapeutics, which is also on track\n to initiate a confirmatory phase III clinical study for KIACTA™, a drug\n candidate developed by BELLUS Health for the treatment of AA\n amyloidosis, during the fourth quarter of 2010. This study represents\n an important milestone for BELLUS Health and its shareholders. We also\n expect to complete the on-going phase I clinical study for NRM8499 in\n the treatment of Alzheimer's disease during the quarter and anticipate\n the results of this study to be available in the first quarter ...